NCT05481307

A Study to Evaluate Pharmacokinetic/Pharmacodynamic Drug-drug Interaction and Safety/Tolerability Between RLD2202 and RLD2203

An Open-label Phase 1 Study to Evaluate PK/PD Drug-drug Interactions and Safety/Tolerability Between RLD2202 and RLD2203 in Healthy Adult Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Hanmi Pharmaceutical Company Limited · Industry
• Sex: All
• Age: 19 Years – 50 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate pharmacokinetic/pharmacodynamic drug-drug interactions and safety/tolerability between RLD2202 and RLD2203 in healthy adult subjects

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	RLD2202	Take it once a day per period
DRUG	RLD2203	Take it once a day per period

Timeline

• Start date: 2022-08-02
• Primary completion: 2022-10-25
• Completion: 2022-10-25
• First posted: 2022-08-01
• Last updated: 2023-09-22

Locations

1 site across 1 country: South Korea